Uptick Newswire interviews Applied BioSciences for The First time on the Stock Day Radio podcast and Discuses the Growth of Their CBD Product Lines

LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Applied BioSciences Corp. (APPB) is a diversified cannabinoid therapeutics company that specializes in the medical,bioceutical, and pet health industries. The President of Applied BioSciences, Chris Bridges, joined Stock Day's Everett Jolly for the first time to discuss the Company's newly expanded product line, as well as their goals for growth going forward.

Jolly began the interview by asking Bridges for a little bit of background information on the Company, as well as himself. Bridges responded, "We're a diversified company focused primarily on the CBD market. We have several different brands under our umbrella." Bridges went on to explain that these included consumer-based brands and their product lines, as well as Herbal Pet, which is a pet-focused brand.

Speaking of his own background, Bridges the stated, "Primarily my background is as a tech entrepreneur and in the payment space. I have been building companies since I was in my early 20's, and came onboard with Applied BioSciences about two years ago and have been really excited about building this company."

Jolly noted the crowded CBD industry given the recent popularity of these products and then asked, "What makes your CBD products so special?" Bridges expanded on the uniqueness of his product line and explained, "What makes our products special is that they are completely organic and free of poisons and pesticides. We have done a great job at creating the best-in-class CBD products out there."

Bridges then discussed the estimated growth of the CBD market, noting that by 2022 this industry will be worth around $22 Billion. Bridges added, "What drove us to create these product lines was focusing on specific targets. We're looking to achieve products that really solve specific problems."

The interview then turned to the discussion of one of the Company's brands, Herbal Pet, which has been growing steadily as a pet line under Bridge's leadership. Jolly inquired, "When is this brand really going to come to fruition and how big is the demand for this segment?"

Bridges responded, "We're starting to push the direct to consumer sales, as well as wholesale for the products. There's a massive and explosive growth for pet-oriented products around CBD. We're really excited about the potential of this one. It's one of the biggest growing brands under our umbrella."

Bridges then discussed the Company's recently closed deal for financing in the amount of $1 Million and explained that they intend to use the funds for the pure growth and expansion of their umbrella brands and their product lines.

The interview closed with Bridges sharing that the team behind Applied BioSciences is truly special and incredibly experienced in the growth of successful companies. Bridges then continued, "We're building a great platform and expect to be one of the great leaders in this industry."

To learn more about Applied BioSciences Corp. listen to the full podcast: https://upticknewswire.com/featured-interview-president-chris-bridges-of-applied-biosciences-corp-otcqb-appb/.

About Applied BioSciences Corp.:

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical,bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact:

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line. Official Website: www.appliedbiocorp.com

Safe Harbor Statement:

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as ''anticipate", ''believe'', ''estimate'', ''expect'', ''intend'' and similar expressions, as they relate to Applied Biosciences Corp. (the ''Company'') or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company's ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.